U.K. Pharmacovigilance Market (2021 - 2028) Size, Share & Trends Analysis Report By Service Provider (Contract Outsourcing, In-house), By Product Life Cycle, By Type, By Process Flow, By Therapeutic Area, By End-use, And Segment Forecasts

Market Segmentation

U.K. Pharmacovigilance Service Provider Outlook (Revenue, USD Million, 2016 - 2028)
- In-house
- Contract Outsourcing
U.K. Pharmacovigilance Product Life Cycle Outlook (Revenue, USD Million, 2016 - 2028)
- Pre-clinical
- Phase I
- Phase II
- Phase III
- Phase IV
U.K. Pharmacovigilance Type Outlook (Revenue, USD Million, 2016 - 2028)
- Spontaneous Reporting
- Intensified ADR Reporting
- Targeted Spontaneous Reporting
- Cohort Event Monitoring
- EHR Mining
U.K. Pharmacovigilance Process Flow Provider Outlook (Revenue, USD Million, 2016 - 2028)
- Case Data Management
  - Case Logging
  - Case Data Analysis
  - Medical Reviewing & Reporting
- Signal Detection
  - Adverse Event Logging
  - Adverse Event Analysis
  - Adverse Event Review & Reporting
- Risk Management System
  - Risk Evaluation System
  - Risk Mitigation System
U.K. Pharmacovigilance Therapeutic Area Outlook (Revenue, USD Million, 2016 - 2028)
- Oncology
- Neurology
- Cardiology
- Respiratory Systems
- Others
U.K. Pharmacovigilance End-use Outlook (Revenue, USD Million, 2016 - 2028)
- Pharmaceuticals
- Biotechnology Companies
- Medical Device Manufacturers
- Others

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments